Innovations in uterine fibroid therapy

Authors: McCarthy-Keith, Desireéé M; Armstrong, Alicia Y

Source: Therapy, Volume 8, Number 2, March 2011 , pp. 189-200(12)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Uterine fibroids are benign tumors that are highly prevalent among reproductive-aged women. Hysterectomy remains the only definitive treatment for symptomatic uterine fibroids; however, uterine-sparing treatment options are needed for women desiring future fertility or uterine preservation. Several alternative treatments exist, but these therapies are limited by significant fibroid recurrence within a few years of treatment or significant side effects. Interventional radiology procedures now extend to the management of fibroids and many medical therapies for treatment of symptomatic fibroids are available or are under investigation in clinical trials. Long-term outcome data for newer medical therapies are needed to determine which therapies offer a definitive advantage over traditional therapies. Future investigations into the molecular biology of fibroids will pave the way for the development of innovative therapies in the treatment and prevention of these highly prevalent gynecologic tumors.

Keywords: aromatase inhibitor; fibroid; hysterectomy; magnetic resonance-guided focused ultrasound surge; myomectomy; uterine artery embolization

Document Type: Research article

DOI: http://dx.doi.org/10.2217/thy.10.90

Affiliations: 1: 1Program in Reproductive & Adult Endocrinology, Building 10, CRC, Room 1E-1-3140, 10 Center Drive MSC 1109, Bethesda, MD 20892-1109, USA

Publication date: 2011-03-01

More about this publication?

Therapy provides a forum for the rapid publication of clinical research findings in medicine, augmented with commentary and analysis on highly topical themes from international experts.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites